Table 2.
Results of included studies
| Study | Indication and index test | TP | FN | FP | TN | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | |
|---|---|---|---|---|---|---|---|---|
| Rinne and colleagues [22] |
N-staging and M-staging |
PET |
4 |
0 |
11 |
37 |
100 (40 to 100) |
77 (63 to 88) |
| Crippa and colleagues [27] |
N-staging |
PET |
17 |
2 |
3 |
16 |
90 (66.9 to 98.7)b |
84 (60.4 to 96.6)b |
| Eigtved and colleagues [24] |
M-staging |
PET |
28 |
1 |
4 |
5 |
97 (82 to 100) |
56 (21 to 86) |
| Klein and colleagues [21] |
N-staging |
PET |
2 |
1 |
0 |
14 |
67 (9.4 to 99.2)b |
100 (76.8 to 100)b |
| Acland and colleagues [18] |
N-staging |
PET |
0a |
14a |
7a |
29a |
0 (0 to 23.2)b |
80,6b (64.0 to 91.8)b |
| Belhocine and colleagues [19] |
N-staging |
PET |
1a |
5a |
1a |
14b |
16.7b (0.4 to 64.1)b |
93.3b (68.1 to 99.8)b |
| Reinhardt and colleagues [29] |
M-staging |
PET |
23 |
2 |
1 |
41 |
92 (74.0 to 99.0)b |
98 (87.4 to 99.9)b |
| Hafner and colleagues [25] |
M-staging |
PET |
0 |
0 |
2 |
98 |
– |
98 d (93.0 to 99.8)d |
| N-staging |
PET |
2 |
24 |
0 |
74 |
8 (0.9 to 25.1)b |
100 (95.1 to 100)b |
|
| Fink and colleagues [20] |
N-staging |
PET |
1 |
7 |
0 |
40 |
13 (0 to 53) |
100 (91 to 100) |
| Vereecken and colleagues [26] |
N-staging |
PET |
4a |
6a |
27a |
6a |
40.0b (12.2 to 73.8)b |
18.2b (7.0 to 35.5)b |
| Brady and colleagues [45] |
N-staging and M-staging |
PET |
30 |
14 |
5 |
54 |
68 (52 to 81) |
92 (81 to 97) |
| Maubec and colleagues [28] |
N-staging and M-staging |
PET/CT |
1b |
5b |
5 |
14 |
17 (0.4b to 64) |
74 (49 to 91) |
| Strobel and colleagues [36] |
N-staging and M-staging |
PET/CT |
45 |
8 |
3 |
68 |
85 (72.4 to 93.3)b |
96 (88.1 to 99.1)b |
| PET/CT and separate CT |
52 |
1 |
4 |
67 |
98 (89,9 to 100)b |
94 (86.2 to 98.4)b |
||
| Singh and colleagues [23] |
N-staging |
PET/CT |
2 |
12 |
2 |
36 |
14.3 (2.5 to 44) b |
94.7 (81 to 99) |
| Bastiaannet and colleagues [35] |
M-staging |
PET |
68 |
11 |
11 |
161 |
86.1b (76.5 to 92.8)b |
93.6b (88.8 to 96.8)b |
| CT |
61 |
17 |
11 |
162b |
78.2b (67.4 to 86.8)b |
93.6b (88.9 to 96.8)b |
||
| Veit-Haibach and colleagues [37] |
N-staging |
PET/CT |
5b |
8 |
0 |
43b |
38.5 (14 to 68) |
100 (92 to 100) |
| PET |
5b |
8 |
0 |
43b |
38.5 (14 to 68) |
100 (92 to 100) |
||
| CT |
3b,c |
10 |
0 |
43b,c |
23.1 (5 to 53) |
100 (92 to 100) |
||
| M-staging |
PET/CT |
5b |
7 |
3 |
41b |
41.7 (15 to 72) |
93.2 (81 to 99) |
|
| PET |
4b |
8 |
4 |
40 b |
33.3 (9 to 65) |
90.9 (78 to 97) |
||
| CT |
3b,c |
9 |
3 |
41b,c |
25.0 (5 to 57) |
93.2 (81 to 99) |
||
| Aukema and colleagues [34] | N-staging | PET/CT | 26 | 4 | 1 | 39 | 86.7b (69.3 to 96.2)b | 97.5b (86.8 to 99.9)b |
CI, confidence interval; CT, computed tomography; FN, false-negative; FP, false-positive; PET, positron emission tomography; TN, true-negative; TP, true-positive;
aData were extracted from primary study.
bOur own calculation.
cThe combination of TP and TN is reported in Table 3 of the study publication. Our own calculation of these values was possible because of the additional information provided in the publication.